多药学独立预测淋巴细胞癌患者的生存,住院和感染情况
Christian Brieghel1,2, Thomas Lacoppidan1, Esben Packness1,3
1Department of Hematology Copenhagen University Hospital-Rigshospitalet Copenhagen Denmark.
HemaSphere
|July 17, 2025
概括
多药性,或多种药物的使用,与淋巴细胞癌患者的结果更差有关. 处方药的数量是生存,住院和感染风险的强有力的预测指标.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 多药性是常见的在患有淋巴细胞癌 (LC) 患者由于多病症.
- 它可能会限制治疗选择,并影响患者的治疗结果.
研究的目的:
- 研究多药对淋巴癌患者的临床影响.
- 为了确定药物历史是否可以作为预后标记.
主要方法:
- 利用来自丹麦处方注册表的诊断前1年的药物 anamnesis 对46,803名新诊断的LC患者.
- 与整体存活率 (OS),住院和严重感染相关的药物数据 (药物类别,多药,药物数量).
- 进行了多变量分析,调整了年龄,性别,并发病率和预后指数.
主要成果:
- 39种药物类别与OS有关,29种与住院治疗有关,27种与严重感染有关.
- 多药性 (≥5种药物) 与不良结果的风险增加有关 (HR 1.4).
- 越来越多的药物逐渐分层化OS,住院和严重感染风险 (高达HR1.9).
- 在特定的淋巴瘤亚型和多发性骨髓瘤中,观察到更多药物治疗的下一次治疗时间更短.
结论:
- 一年的药物历史,特别是药物的数量,是淋巴细胞癌症患者的强大的独立预后和预测标记.
- 这一指标应作为临床试验和临床实践中LC患者的基线特征纳入.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
380
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
